sea change

Houston robotics company secures deal with Brazilian energy giant

Nauticus Robotics has secured a new customer, taking expanding its services to Brazil. Photo courtesy of Nauticus

Houston-based Nauticus Robotics, a developer of autonomous ocean robots, has landed a deal to supply its equipment to one of the world’s largest energy companies — a deal that eventually could blossom into $100 million worth of contracts.

Under the deal, Nauticus will dispatch its Aquanaut autonomous subsea robot to support offshore oil exploration activities carried out by Brazil’s Petrobras. Specifically, Aquanaut — propelled by artificial intelligence-enabled software — will supervise infield inspection services over a two-month span.

The deal with Brazil’s Petrobras represents Nauticus’ entry into the South American market and puts Nauticus in a position to score several Petrobras contracts that could collectively be valued at $100 million. Both companies are publicly traded.

Nicolaus Radford, founder and CEO of Nauticus, says Brazil offers a significant market opportunity for his company, as South America’s largest nation boasts one of the world’s most active offshore energy basins.

“A contract with [a] worldwide leading operator for Nauticus speaks to the state-of-the-art technologies of our autonomous robots as we further penetrate the global markets,” Radford says in a news release.

Petrobras is one of the world’s biggest offshore operators, managing 57 platforms, operating 10,000 miles of oil and gas pipelines, and producing the equivalent of 2.6 million barrels of oil per day. The company generated $124.47 billion in revenue last year.

Founded in 2014, Nauticus posted revenue of $11.4 million in 2022. The company went public last year through a $560 million merger with a special purpose acquisition company (SPAC). Nauticus recently opened a new office in The Ion, in addition to their Webster office.

“I see Nauticus being the preeminent ocean robotics company. I want Nauticus to be an empire. It starts small but it grows — and it grows in many different ways, and we’re exploring all of those different ways to grow,” Radford told InnovationMap in May. “We’re leading a technology renaissance in the marine space — and that happens only a few times in an industry.”

------

This article originally ran on EnergyCapital.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted